Cypherpunk Technologies Inc. (CYPH) Stock Analysis

Cypherpunk Technologies (NASDAQ: CYPH), formerly Leap Therapeutics, transformed in November 2025 after a $58.88 million Winklevoss Capital-led PIPE, adopting a Zcash treasury strategy while placing its oncology programs in a wholly owned Leap subsidiary. Its two economic engines are ZEC treasury appreciation and mining rewards, plus potential licensing or spin-out proceeds from sirexatamab. At August 2026, it held 323,394.38 ZEC, roughly 1.92% of circulating supply, and operated 4.2 GSol/s of hashrate—about 18% of the network. Q2 2026 revenue remained $0, but net income was $39.39 million, or $0.18 diluted EPS, largely because of a $46 million unrealized ZEC gain; cash was $7.62 million and equity was $139.32 million. At the cited $2.80 share price, market capitalization was $301.73 million and enterprise value $164.72 million; P/B was 2.17x, while trailing P/E is distorted by token gains. **The investment is chiefly a leveraged ZEC/NAV and mining bet, not a conventional earnings story.** Near-term catalysts include mining execution, ZEC adoption and price, and a partnership or spin-out for the Phase 3-ready oncology asset. The report’s probability-weighted five-year target is $5.07, with substantial downside in its bear case.